Clinical trials: Becotatug Vedotin
Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma
Becotatugvedotin Plus Pucotenlimab in EGFR-Positive Advanced Gastric/GEJ Adenocarcinoma
Advanced gastric cancer (AGC) and gastroesophageal junction (GEJ) adenocarcinoma remain associated with poor prognosis after failure of first-line systemic therapy.
- Conditions
- Gastric Cancer, Gastroesophageal Junction (GEJ) Adenocarcinoma, Becotatug Vedotin, Pucotenlimab
- Trial name
- NCT07692334
- Testing
- Becotatug Vedotin (MRG003), Pucotenlimab
- Volunteers
- 28 people
- Sponsor
- West China Second University Hospital
Squamous Cell Carcinoma of the Anal Canal
Becotatug Vedotin Plus Pucotenlimab and Capecitabine Followed by Concurrent Chemoradiotherapy-Immunotherapy for Locally Advanced Squamous Cell Carcinoma of the Anal Canal
This is a single-arm, exploratory clinical study intended to enroll patients with EGFR-positive Locally Advanced Squamous Cell Carcinoma of the Anal Canal (T2-4N0-1M0).
- Trial name
- NCT07800000
- Testing
- Induction therapy, Concurrent chemoradiotherapy-immunotherapy, Maintenance therapy
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Wang Xin
Pancreatic Cancer
Becotatug Vedotin Plus Anti-PD-1 and S-1 in Patients With EGFR-Positive Advanced Pancreatic Cancer Who Have Failed at Least One Line of Standard Therapy
This is a prospective, single-arm, single-center exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of a triplet regimen-becotatug vedotin combined with anti-PD-1 and S-1-in patients with…
- Trial name
- NCT07892573
- Testing
- Becotatug Vedotin, Anti-PD-1 antibody, S-1
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Ningbo Medical Center Lihuili Hospital
Biliary Tract Cancer (BTC), EGFR-positive Advanced Biliary Tract Carcinoma
Becotatug Vedotin Plus Pucotenlimab for Advanced Biliary Tract Cancer, Phase II
Biliary tract carcinoma (BTC), including cholangiocarcinoma and gallbladder cancer, is a highly aggressive digestive system malignancy with limited treatment options after failure of first-line standard chemotherapy.
- Trial name
- NCT07649980
- Testing
- Becotatug Vedotin, Pucotenlimab
- Volunteers
- 30 people
- Sponsor
- HuiKai Li
Adenoid Cystic Carcinoma, Sinonasal Carcinoma
A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma
This prospective, multicenter clinical study aims to evaluate the efficacy and safety of neoadjuvant therapy with MRG003 (Becotatug vedotin) combined with epirubicin in patients with EGFR-positive, unresectable recurrent…
- Trial name
- MRG003-SACC (NCT07522879)
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Eye & ENT Hospital of Fudan University
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
This study plans to enroll patients with histologically or cytologically confirmed locally recurrent nasopharyngeal carcinoma. After signing informed consent, eligible subjects will receive three cycles of standard-dose becotatug…
- Trial name
- NCT07781358
- Testing
- Becotatug Vedotin, PD-1 / PD-L1 monoclonal antibody
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Hongmeng Yu
Nasopharyngeal Cancinoma (NPC)
Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy
Based on the short-term efficacy and plasma EBV DNA levels following immuno-induction chemotherapy, patients with locally advanced nasopharyngeal carcinoma who derive different benefits from this treatment can be identified.
- Trial name
- NCT07496190
- Testing
- Becotatug vedotin
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma
Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors
There is a significant unmet medical need for effective therapies for pediatric relapsed/refractory solid tumors. EGFR is highly and stably expressed in multiple pediatric solid tumor subtypes, and adult Phase I data of Becotatug…
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Nasopharyngeal Carcinoma, Lymphoepithelial Carcinoma, Rhabdomyosarcoma
- Trial name
- MRG003 (NCT07584499)
- Testing
- Becotatug Vedotin
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Non-Small Cell Carcinoma of Lung, Locally Advanced
Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLC
This is a prospective, single-arm phase II clinical study enrolling patients with locally advanced unresectable non-small cell lung cancer.
- Trial name
- NCT07882940
- Testing
- Becotatug Vedotin (MRG003)+pucotenlimab+platinum, radiotherapy
- Volunteers
- 24 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma
MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma
This is a multicenter, prospective, randomized, controlled Phase II trial evaluating the safety and efficacy of MRG003 (Becotatug vedotin) combined with Toripalimab versus Toripalimab alone as neoadjuvant therapy for…
- Trial name
- NCT07677475
- Testing
- MRG003 (Becotatug vedotin) and Toripalimab, Toripalimab
- Where
- China
- Volunteers
- 65 people
- Sponsor
- Dongguan People's Hospital
Metastatic Colorectal Cancer
Becotatug Vedotin Plus Pucotenlimab for Metastatic Colorectal Cancer
The BECOME trial will study whether becotatug vedotin combined with pucotenlimab can shrink tumors and how safe this treatment is in adults with colorectal cancer that has returned or spread after at least two prior lines of…
- Trial name
- NCT07884188
- Testing
- Becotatug Vedotin (MRG003), Pucotenlimab
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Fudan University
Esophageal Squamous Cell Carcinoma
Becotatug Vedotin Plus Tislelizumab and Low-Dose Lenvatinib for Advanced Esophageal Squamous Cell Carcinoma, Phase II
Immunotherapy combined with chemotherapy has become the first-line standard of care for advanced esophageal squamous cell carcinoma (ESCC), significantly improving patient survival.
- Trial name
- NCT07686926
- Testing
- Becotatug Vedotin, Tislelizumab, Lenvatinib
- Volunteers
- 36 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Hepato Cellular Carcinoma (HCC)
Becotatug Vedotin (MRG003) in Previously Treated Advanced Hepatocellular Carcinoma
This study will evaluate the efficacy and safety of Becotatug vedotin, MRG003, in previously treated advanced hepatocellular carcinoma (HCC).
- Trial name
- NCT07536789
- Testing
- MRG003
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Cutaneous Squamous Cell Carcinoma (CSCC)
Pucotenlimab Combined With Becotatug Vedotin in Advanced Cutaneous Squamous Cell Carcinoma
Study Design The study plans to enroll 38 patients. A Simon's two-stage design is employed. Based on historical data, the objective response rate (ORR) for patients meeting the inclusion criteria and receiving PD-1 inhibitor…
- Trial name
- NCT07394244
- Testing
- Pucotenlimab, Becotatug Vedotin
- Where
- China
- Volunteers
- 38 people
- Sponsor
- Fudan University
Nasopharyngeal Carcinoma (NPC)
Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC
This study is a multicenter, randomized, controlled phase III clinical trial aiming to investigate the efficacy and safety of Becotatug Vedotin induction therapy followed by concurrent chemoradiotherapy (CCRT) combined with…
- Trial name
- NCT07459296
- Testing
- Becotatug Vedotin, Sintilimab, Cisplatin
- Where
- China
- Volunteers
- 266 people
- Sponsor
- First Affiliated Hospital of Guangxi Medical University
Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma HNSCC
Neoadjuvant Becotatug Vedotin Plus Pucotenlimab and Cisplatin for Locally Advanced Head and Neck Squamous Cell Carcinoma
This clinical trial aims to evaluate the efficacy and safety of Becotatug Vedotin (EGFR-Targeting ADC) in combination with Pucotenlimab and Cisplatin as neoadjuvant therapy for patients with locally advanced head and neck…
- Trial name
- NCT07393477
- Testing
- Combination Therapy with Becotatug Vedotin, Pucotenlimab, and Cisplatin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sir Run Run Shaw Hospital
Head and Neck Squamous Cell Carcinoma
A Phase II Clinical Trial of Anti-EGFR Antibody-drug Conjugate (ADC) Combined With or Without Immune Checkpoint Inhibitors in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
A Randomized, Non-comparative Phase II Clinical Trial of Becotatug Vedotin Combined with or without Immune Checkpoint Inhibitors (Penpulimab/Ivonescimab) in the Neoadjuvant Treatment of Resectable Locally Advanced Head and Neck…
- Trial name
- NCT07381075
- Testing
- Becotatug Vedotin, Becotatug Vedotin Combined with Penpulimab, Becotatug Vedotin Combined with Ivonescimab
- Where
- China
- Volunteers
- 90 people
- Sponsor
- West China Hospital
Esophageal Squamous Cell Carcinoma
Becotatug Vedotin ± Anti-PD-1 in Pretreated Advanced ESCC
This study will test a new potential treatment for advanced esophageal squamous cell cancer (ESCC) for patients whose initial treatment has stopped working.
- Trial name
- NCT07403136
- Testing
- Vebrekotuzumab, PD-1 antibody
- Where
- China
- Volunteers
- 104 people
- Sponsor
- Fudan University
Head and Neck Squamous Cell Carcinoma
Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study
This is a prospective, single-arm, multi-center, Phase II clinical trial evaluating the efficacy and safety of neoadjuvant becotatug vedotin (an anti-EGFR antibody-drug conjugate) combined with pucotenlimab (HX008, an anti-PD-1…
- Trial name
- GATEWAY (NCT07589049)
- Testing
- Becotatug Vedotin, Pucotenlimab
- Where
- 12 sites in China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma, HNSCC
Becotatug Vedotin Plus Pucotenlimab and Platinum Chemotherapy in Locally Advanced Epidermal Growth Factor Receptor (EGFR)-Positive Head and Neck Squamous Cell Carcinoma
This prospective, single-arm, multicenter phase II trial aims to evaluate the efficacy and safety of neoadjuvant beccotatug vedotin combined with pucotenlimab and cisplatin in patients with locally advanced epidermal growth…
- Trial name
- NCT07814287
- Testing
- Becotatug Vedotin, Pucotenlimab, and Cisplatin
- Where
- 2 sites in China
- Volunteers
- 40 people
- Sponsor
- Xuekui Liu